Novavax reported $448.43M in Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Adma Biologics ADMA:US $ 139.81M 1.39M
Agenus AGEN:US $ 13.7M 0.48M
Astrazeneca AZN:US $ 29528M 1571M
AstraZeneca AZN:LN 29528M 1571M
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Dynavax Technologies DVAX:US $ 221.03M 0.27M
Genocea Biosciences GNCA:US $ 7.65M 1.14M
Geron GERN:US $ 50.42M 0.24M
GlaxoSmithKline GSK:LN 22111M 11217M
Mannkind MNKD:US $ 376.46M 8.08M
Moderna Inc MRNA:US 762M 44M
Novartis NVS:US $ 31031M 244M
Novavax NVAX:US $ 448.43M 7.93M
Pain Therapeutics PTIE:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 142.18M 0.14M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M